5/6/2009 | CV | Nabi Biopharmaceuticals buys $10.4 million in 2.875% convertible notes for $10.1 million
|
3/11/2009 | CV | Nabi repurchases $18.7 million in 2.875% convertible senior notes
|
1/27/2009 | SS | Nabi Biopharmaceuticals investor buys 122,100 shares
|
11/6/2008 | CV | Nabi buys back $25.7 million in 2.875% convertible senior notes
|
2/29/2008 | SS | DellaCamera owns 6.4% of Nabi Biopharmaceuticals
|
2/28/2008 | CV | Nabi repurchases $38.8 million of 2.875% convertible senior notes
|
1/31/2008 | SS | DellaCamera makes recommendations to new Nabi CEO
|
1/23/2008 | SS | Market Commentary: Ambac, MBIA still waiting; Yahoo! set for layoffs; Quebecor in court; Fifth Third still after First Charter
|
1/22/2008 | SS | Nabi Biopharmaceuticals to begin strategic review process
|
12/7/2007 | SS | Nabi buys back more than 3 million shares from Chapman Capital
|
12/7/2007 | CV | S&P: Nabi view stable
|
12/4/2007 | SS | Market Commentary: Biotest buys Nabi's Biologics unit; Doral shares slide; Virginia Financial, FNB shareholders OK merger
|
9/11/2007 | SS | Market Commentary: Nabi up after selling unit to Biotest; United Retail Group soars after Redcats acquisition news
|
9/11/2007 | CV | Market Commentary: Countrywide continues slide; Thornburg up; ImClone drug sparks investor hopes; Nabi trades big, if not much
|
6/15/2007 | SS | Chapman Capital supports sale of Nabi's biologics division
|
6/15/2007 | SS | Nabi shareholder Chap-Cap may choose to recommend alternatives to company
|
5/11/2007 | SS | Third Point has 11.4% stake in Nabi Biopharmaceuticals
|
11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
11/13/2006 | BT | Market Commentary: Solexa up 20.5%, Illumina down 12% on stock merger; Nabi slips; Favrille falls 22%; Ariad steady
|
10/25/2006 | BT | Nabi Biopharmaceuticals reduces cash burn rate by 81% from first quarter
|
10/16/2006 | BT | Market Commentary: Vical up on PIPE; Amgen sinks on FDA delay; Critical up 16%; Omrix off 14.5% on profit taking
|
10/12/2006 | BT | Nabi: sale of PhosLo will help cut 2006 cash burn to less than $30 million
|
10/12/2006 | BT | Market Commentary: Genzyme gets AnorMED nod but hurt by 3Q; Nabi up 6% on asset sale; Trimeris off 13% on warning
|
9/28/2006 | BT | Market Commentary: Abraxis seeks partner, soars 7%; Somaxon higher; Dynavax slips; Exact Sciences, Immunicon slide
|
9/28/2006 | CV | Market Commentary: Amkor up on revised offer; Nabi gains on sale hopes; ImClone rides stock rally; Brandywine quiet in gray
|
9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
8/29/2006 | BT | Nabi obtains rights to ProMetic's hyperimmune immunoglobulin extraction technology
|
8/21/2006 | BT | ProMetic signs strategic license agreement up to $18 million with Nabi
|
8/2/2006 | BT | Market Commentary: Pozen pumped by partnership; Biovail battered by patent loss; Gene Logic gains on layoffs
|
7/27/2006 | BT | Market Commentary: Adams hit 4%; Conor slips after follow-on; Diomed pockets $10 million from PIPE; Oscient gains
|
7/26/2006 | BT | Nabi Biopharmaceuticals credits PhosLo sales with rise in second-quarter revenues to $29.9 million
|
7/18/2006 | BT | Nabi's PhosLo shown to provide superior control of serum phosphorus in end-stage renal disease
|
7/13/2006 | BT | Nabi: FDA committee recommends Nabi-HB intravenous to prevent hepatitis B
|
6/29/2006 | BT | Nabi Biopharmaceuticals, Kedrion to develop Civacir in hepatitis C
|
6/29/2006 | BT | Market Commentary: Invitrogen, Geron rise on pact; other stem cell names higher; Keryx up 8%; Nabi up over 2%
|
6/15/2006 | BT | Market Commentary: Nabi rises on renewed pressure; Anadys dives 18%; Discovery Labs surges 26%; Auxilium off
|
5/30/2006 | BT | Nabi moves toward licensure of hepatitis B antibody product
|
5/24/2006 | BT | Nabi begins phase 2b proof-of-concept study of NicVAX nicotine addiction vaccine
|
5/1/2006 | BT | Nabi Pharmaceuticals develops strategic business plan to increase cash, shareholder value
|
4/28/2006 | BT | Inhibitex to halt manufacture of Veronate trial material, end relationship with Nabi
|
4/26/2006 | BT | Nabi, Sanofi Pasteur sign supply, manufacturing agreement for rabies product
|
4/19/2006 | BT | Nabi Pharmaceuticals shareholder Knott pressures management to explore strategic alternatives
|
4/19/2006 | BT | Market Commentary: Genzyme crashes on miss; Nektar dips, ends higher; MannKind off; Icon better; Nabi adds another 4%
|
4/18/2006 | BT | Market Commentary: Gilead pitching jumbo convertible; CV Therapeutics bags $200 million; Labopharm deal emerges; Nabi up
|
4/11/2006 | BTCV | S&P downgrades Nabi Biopharmaceuticals
|
4/4/2006 | BT | Market Commentary: Valeant up on restructuring; Nabi gains; Avanir rises on drug filing; Enzon higher; ViroPharma eyed
|
4/3/2006 | BT | Nabi acquires U.S., Canadian commercialization rights to Fresenius' antibody product
|
3/22/2006 | BT | Market Commentary: Cephalon seesaws; Nabi zooms; Endo drops; Insmed off; Elan, Biogen drop; King launches deal
|
3/21/2006 | BT | Nabi says to continue Gram-positive program after panel review
|
3/9/2006 | BT | Nabi's NicVAX for nicotine addiction receives FDA fast track designation
|
2/24/2006 | BT | Nabi Biopharmaceuticals terminates StaphVAX manufacturing agreement with Cambrex
|
2/14/2006 | BT | Nabi Biopharmaceuticals moves forward with anti-smoking vaccine
|
2/7/2006 | BT | Nabi announces positive phase 1 results for two bacterial infection vaccines
|
2/2/2006 | BT | Nabi receives fast track designation for Civacir
|
2/2/2006 | BT | Market Commentary: Valera debut shares gain 10%; Theravance up; ImClone sinks; Nabi rockets; Teva pressured
|
1/26/2006 | BT | Nabi says NicVAX smoking cessation vaccine well-tolerated in phase 2 study
|
12/20/2005 | BT | Nabi says expert panel will assess company's infections program, phase 3 failure of StaphVAX
|
12/19/2005 | BT | Nabi closes European operations to save expenses in response to StaphVAX phase 3 failure
|
11/23/2005 | BT | White Mountain drops Nabi coverage
|
11/21/2005 | BT | Nabi says new study suggests PhosLo may not cause calcium problems
|
11/2/2005 | BTCV | S&P cuts Nabi view to negative
|
11/2/2005 | BT | White Mountain cuts Nabi to sell
|
11/2/2005 | BT | Bear Stearns cuts Nabi to peer perform
|
11/2/2005 | BT | Market Commentary: Novavax stock slips 12.3% on $18 million direct placement; convertible biotech names mixed
|
11/1/2005 | BT | Market Commentary: Cell Therapeutics prices $82 million notes to yield 6.75%; Nabi's stock dives on failed clinical trial
|
11/1/2005 | CV | Market Commentary: Qwest, Chesapeake Energy to price $2 billion-plus in convertibles; new IPC paper trades actively
|
11/1/2005 | BT | Nabi halts development on StaphVAX after it fails phase III trial
|
10/31/2005 | BT | Market Commentary: NeoPharma skyrockets on new CEO; Charles River Labs higher; Nabi, Indevus, Invitrogen up
|
9/13/2005 | BT | Nabi kept by Thomas Weisel at peer perform
|
8/31/2005 | BT | Nabi initiated by Thomas Weisel at peer perform
|
8/9/2005 | BT | Nabi kept by Bear Stearns at outperform
|
7/20/2005 | BT | Nabi initiated by Global Crown at underweight
|
7/20/2005 | BT | Nabi maintained by Bear Stearns at outperform
|
5/18/2005 | CV | Nabi Biopharmaceuticals greenshoe partially exercised, raising convertibles to $112.4 million
|
4/14/2005 | CV | Market Commentary: Nabi trades lower; Chesapeake up; GM, Ford ditched; AMD spreads blown out
|
4/14/2005 | CV | New Issue: Nabi sells downsized $100 million convertible to yield 2.875%, up 30%
|
4/14/2005 | CV | S&P rates Nabi Biopharm convertibles B
|
4/13/2005 | CV | Market Commentary: Ford picks up buyers as selling in supplier Lear accelerates; Imclone crushed on delay; Goodyear skids
|
4/12/2005 | CV | Market Commentary: El Paso reoffered at 97.5; Ford off as exodus goes on; sell-off targets high-risk issues like Charter, Saks
|
4/11/2005 | CV | Nabi $125 million convertible talked to yield 2.375%-2.875%, up 30%-35%
|
4/11/2005 | CV | Market Commentary: El Paso at bat with sweeter terms; Nabi emerges; Ford plummets in wake of warning; Impax steadies
|
12/7/2004 | CV | Nabi Pharmaceuticals files $175 million shelf
|
5/7/2002 | CV | Salomon adds three, removes three from recommended portfolio
|
10/3/2001 | CV | Moody's warns on wireline telecom sector
|